Celestica Q4 EPS $0.56 Beats $0.54 Estimate, Sales $2.04B Beat $1.97B Estimate

Celestica (NYSE:CLS) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.54 by 3.7 percent. This is a 27.27 percent increase over earnings of $0.44 per share from the same

Celestica (NYSE:CLS) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.54 by 3.7 percent. This is a 27.27 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $2.04 billion which beat the analyst consensus estimate of $1.97 billion by 3.71 percent. This is a 35.12 percent increase over sales of $1.51 billion the same period last year.

Total
0
Shares
Related Posts
Read More

Immutep Announced Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the Independent Data Monitoring Committee (IDMC) for the randomised, controlled Phase IIb TACTI-003 trial has reviewed initial safety data and recommended continuing the trial with no modificatio

IMMP